The use of off-label medications in substance abuse treatment programs

References

• Aletraris L, Bond Edmond M, Roman PM. Adoption of injectable naltrexone in U.S. substance use disorder treatment programs. J Stud Alcohol Drugs. 2015;76(1):143–151.
   PubMed Web of Science ®Google Scholar
• Knudsen HK, Roman PM. Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders. J Stud Alcohol Drugs. 2014;75(3):467–475.
   PubMed Web of Science ®Google Scholar
• Knudsen H, Roman P. Financial factors and the implementation of medications for treating opioid use disorders. J Addict Med. 2012;6(4):280–286.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Caputo F, Capristo E. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37(5):504–508.
   PubMed Web of Science ®Google Scholar
• Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol. 2014;49(6):654–660.
   PubMed Web of Science ®Google Scholar
• Agabio R, Preti A, Gessa GL. Efficacy and tolerability of baclofen in substance use disorders: a systematic review. Eur Addict Res. 2013;19(6):325–345.
   PubMed Web of Science ®Google Scholar
• Gorsane M-A, Kebir O, Hache G, et al. Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates. Subst Abus. 2012;33(4):336–349.
   PubMed Web of Science ®Google Scholar
• Shukla L, Shukla T, Bokka S, et al. Correlates of baclofen effectiveness in alcohol dependence. Indian J Psychol Med. 2015;37(3):370–373.
   PubMedGoogle Scholar
• Kenna GA, Nielsen DM, Mello P, Schiesl A, Swift RM. Pharmacotherapy of dual substance abuse and dependence. CNS Drugs. 2007;21(3):213–237.
   PubMed Web of Science ®Google Scholar
• Rolland B, Paille F, Fleury B, Cottencin O, Benyamina A, Aubin H-J. Off-label baclofen prescribing practices among french alcohol specialists: results of a national online survey. PLoS One. 2014;9(6):e98062.
   PubMed Web of Science ®Google Scholar
• Perinpanayagam J, Abu-Asi MJ, Bustamante S, Kunnumpurath S. Opioid-sparing drugs (ketamine, gabapentin, pregabalin, and clonidine). In: Kaye AD, Vadivelu N, Urman RD, Kaye AD, Vadivelu N, Urman RD, eds. Substance Abuse: Inpatient and Outpatient Management for Every Clinician. New York, NY, US: Springer Science + Business Media; 2015:319–330.
   Google Scholar
• Felicilda-Reynaldo R. Recognizing signs of prescription drug abuse and addiction, part I. Medsurg Nurs. 2014;23(6):391–396.
   PubMedGoogle Scholar
• Hussain SS, Farhat S, Hassan Rat Y, Abbas Z. Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine-naloxone in opioid withdrawal - a hospital based study. J Clin Diagn Res. 2015;9(1):1.
   Web of Science ®Google Scholar
• Longo LP, Campbell T, Hubatch S. Divalproex sodium (depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002;21(2):55–64.
   PubMed Web of Science ®Google Scholar
• Myrick H, Henderson S, Brady KT, Malcom R, Measom M. Divalproex loading in the treatment of cocaine dependence. J Psychoactive Drugs. 2001;33(3):283–287.
   PubMed Web of Science ®Google Scholar
• Halikas JA, Center BA, Pearson VL, Carlson GA, Crea F. A pilot, open clinical study of depakote in the treatment of cocaine abuse. Hum Psychopharmacol Clin Exp. 2001;16(3):257–264.
   PubMed Web of Science ®Google Scholar
• Furieri FA, Nakamura-Palacios EA. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(11):1691–1700.
   PubMed Web of Science ®Google Scholar
• Furieri FA, Oliveira Rwd d, Nakamura-Palacios EM. Gabapentin enhances the recovery of attention and short- term memory in alcoholics. Mind Brain J Psychiatry. 2010;1(1):1–9.
   Google Scholar
• Mason B, Mason BJ, Quello S, et al. Gabapentin treatment for alcohol dependence a randomized clinical trial. JAMA Intern Med. 2014;174(1):70–77.
   PubMed Web of Science ®Google Scholar
• Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB. Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety. Subst Abus. 2016;37(2):286–298.
   PubMed Web of Science ®Google Scholar
• Anton RF, Myrick H, Wright TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011;168(7):709–717.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients. a randomized controlled trial. JAMA. 2000;248(8):963.
   Google Scholar
• Palpacuer C, Duprez R, Huneau A, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018;113(2):220–237.
   PubMed Web of Science ®Google Scholar
• Prince V, Bowling KC. Topiramate in the treatment of cocaine use disorder. Am J Health Syst Pharm. 2018;75(1):e13–e22.
   PubMed Web of Science ®Google Scholar
• Baldaçara L, Cogo-Moreira H, Parreira BL, et al. Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2016;77(3):398–406.
   PubMed Web of Science ®Google Scholar
• Umbricht A, DeFulio A, Winstanley EL, et al. Full length article: topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend. 2014;140:92–100.
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Bisaga A, Nunes EV, Brooks DJ, Levin FR, Pavlicova M. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry. 2012;72(11):950–956.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Xin-Qun W, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013;70(12):1338–1346.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Roache JD, Ait-Daoud N, et al. Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking. Addict Biol. 2013;18(3):405–416.
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75(3):233–240.
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O’Brien CP. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend. 2013;133(1):94–99.
   PubMed Web of Science ®Google Scholar
• Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21–27.
   PubMed Web of Science ®Google Scholar
• Aletraris L, Paino M, Edmond MB, Roman PM, Bride BE. The use of art and music therapy in substance abuse treatment programs. J Addict Nurs. 2014;25(4):190–196.
   PubMed Web of Science ®Google Scholar
• Aletraris L, Roman P. Provision of onsite HIV services in substance use disorder treatment programs: a longitudinal analysis. J Subst Abuse Treat. 2015;57:1–8.
   PubMed Web of Science ®Google Scholar
• Edmond MB, Aletraris L, Paino M, Roman PM. Treatment strategy profiles in substance use disorder treatment programs: a latent class analysis. Drug Alcohol Depend. 2015;153:109–115.
   PubMed Web of Science ®Google Scholar
• Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 2007;87(2–3):164–174.
   PubMed Web of Science ®Google Scholar
• Rogers EM. The Diffusion of Innovations. 4th ed. New York, NY: Free Press; 2003.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2017. Data on Substance Abuse Treatment Facilities. Rockville, MD: Department of Health and Human Services; 2018.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2013. Data on Substance Abuse Treatment Facilities. Rockville, MD: Department of Health and Human Services; 2014.
   Google Scholar
• Mee-Lee DL, Shulman GD, Fishman MJ, Gastfriend DR, Griffith JH. ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders, Revised (ASAM PPC-2R) 2nd ed. Chevy Chase, MD: American Society of Addiction Medicine; 2001.
   Google Scholar
• Stafford RS. Regulating off-label drug use-rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427–1429.
   PubMed Web of Science ®Google Scholar